Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 50.00%-32K | -32.73%-73K | 29.41%-108K | 50.72%-308K | 47.83%-36K | 64.25%-64K | 66.87%-55K | 27.49%-153K | 23.97%-625K | 54.00%-69K |
| Net income from continuing operations | -42.27%-138K | -101.14%-118K | 18.26%-179K | 964.77%9.87M | -23.21%-138K | 50.51%-97K | 1,879.48%10.32M | 13.44%-219K | 22.64%-1.14M | 92.34%-112K |
| Operating gains losses | ---- | ---- | ---- | 266.67%40K | --0 | ---- | 136.36%8K | 3,300.00%32K | 79.83%-24K | 77.78%-28K |
| Remuneration paid in stock | ---- | ---- | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Other non cashItems | 23.53%21K | 100.18%19K | 77.78%16K | -2,160.47%-10.43M | -94.34%15K | 325.00%17K | -10,567.00%-10.47M | -93.43%9K | -0.78%506K | 93.43%265K |
| Change In working capital | 431.25%85K | -68.67%26K | 120.00%55K | 520.59%211K | 35.94%87K | 214.29%16K | 6.41%83K | 126.60%25K | -87.02%34K | -52.24%64K |
| -Change in receivables | 0.00%1K | --0 | 75.00%-1K | -95.65%1K | --0 | 125.00%1K | 500.00%4K | -115.38%-4K | 209.52%23K | 113.33%2K |
| -Change in prepaid assets | 141.67%29K | -112.50%-4K | -125.00%-18K | 203.51%59K | --23K | 144.44%12K | 23.08%32K | 85.71%-8K | -812.50%-57K | --0 |
| -Change in payables and accrued expense | 1,733.33%55K | -36.17%30K | 100.00%74K | 122.06%151K | 3.23%64K | -82.35%3K | -11.32%47K | 157.81%37K | -75.27%68K | -55.71%62K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 50.00%-32K | -32.73%-73K | 29.41%-108K | 50.72%-308K | 47.83%-36K | 64.25%-64K | 66.87%-55K | 27.49%-153K | 23.97%-625K | 54.00%-69K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | ||||||||||
| Cash from discontinued investing activities | ||||||||||
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -2.08%47K | -1.35%73K | -34.90%97K | -48.05%319K | -25.00%48K | -71.76%48K | -57.47%74K | -27.67%149K | -24.01%614K | -46.67%64K |
| Net issuance payments of debt | -7.69%48K | -2.67%73K | -34.67%98K | -47.33%325K | -26.15%48K | -69.41%52K | -57.14%75K | -27.54%150K | -24.01%617K | -46.72%65K |
| Cash dividends paid | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Interest paid (cash flow from financing activities) | 75.00%-1K | --0 | 0.00%-1K | -100.00%-6K | --0 | ---4K | 0.00%-1K | 0.00%-1K | 25.00%-3K | 50.00%-1K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -2.08%47K | -1.35%73K | -34.90%97K | -48.05%319K | -25.00%48K | -71.76%48K | -57.47%74K | -27.67%149K | -24.01%614K | -46.67%64K |
| Net cash flow | ||||||||||
| Beginning cash position | -65.22%8K | 100.00%8K | 137.50%19K | -57.89%8K | -46.15%7K | 4.55%23K | -71.43%4K | -57.89%8K | -42.42%19K | -73.47%13K |
| Current changes in cash | 193.75%15K | ---- | -175.00%-11K | 200.00%11K | 340.00%12K | -77.78%-16K | 137.50%19K | 20.00%-4K | 21.43%-11K | 83.33%-5K |
| End cash Position | 228.57%23K | -65.22%8K | 100.00%8K | 137.50%19K | 137.50%19K | -46.15%7K | 4.55%23K | -71.43%4K | -57.89%8K | -57.89%8K |
| Free cash from | 50.00%-32K | -32.73%-73K | 29.41%-108K | 50.72%-308K | 47.83%-36K | 64.25%-64K | 66.87%-55K | 27.49%-153K | 23.97%-625K | 54.00%-69K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.